function and pancytopenia that required daily red blood cell and platelet transfusions.Three weeks into this hospitalization, her blood cultures were reported to be positive for Mycobacterium chimera, and she was started on a four-drug regimen of rifampin, rifabutin, ethambutol, and clarithromycin, with dramatic clinical improvement. Conclusion Heater-cooler units manufactured by LivaNova prior to September 2014 and used during cardiopulmonary bypass have been linked to M. chimera, which causes a latent infection that may be activated and become disseminated in cases of immunosuppression related to steroid use. Infection is a major complication after cardiac surgery. Risks such as the use of central venous catheters, implantation of foreign material, hypothermia, and allogeneic blood transfusions can all increase the potential for nosocomial infection. [1] [2] [3] [4] A subject of interest involves contaminants in the heater-cooler units (HCUs) of the cardiopulmonary bypass circuit, which may serve as a reservoir and source of infection in the operating room. The HCU functions as a thermoregulator by using reservoirs of filtered tap water as a thermic transfer medium to cool the cardioplegia solution and to alternately cool and warm the patient's blood. Nontuberculous mycobacterium (NTM) is a rare pathogen that can be transmitted via such a moisture-rich environment. Heater-cooler units were first suspected to be the cause of NTM infection in 2002 5 and have recently gained global interest because of newly reported cases. 6, 7 The purpose of this report is to present the case of an NTM aortic valve abscess that appeared five years after mechanical valve replacement. We postulate that the infection -likely caused by a mycobacterium harbored in an HCU -may have been exacerbated by subsequent steroid-induced immunosuppression. In addition, we discuss recommendations on the prevention and diagnosis of HCU infections that, in addition to vigilant HCU cleaning, must also include provider and patient awareness of the risk of NTM infection.
Résumé

Case report
A 63-yr-old woman with a past medical history of aortic coarctation repair in 1963 and mechanical aortic valve replacement in 2010 presented to an outpatient care facility in September 2015 with symptoms of an upper respiratory tract infection. She was prescribed antibiotics and systemic steroids, which improved her symptoms. In January 2016, she presented with malaise and intermittent fevers and was discovered to have anemia and acute kidney dysfunction but no obvious infection. An extensive evaluation was performed, including bone marrow biopsy, which showed granulomas and a fatty aspirate suggestive of amyloidosis. The patient was started on systemic steroids for presumed sarcoidosis and amyloidosis and was referred to us for further evaluation.
At our institution, transesophageal echocardiography (TEE) performed to investigate for potential prosthetic valve endocarditis showed a normally functioning St. Jude mechanical aortic prosthesis. It also revealed aortic root thickening with cavitation consistent with an aortic root abscess and punctate thickening of the mitral valve suggesting possible previous endocarditis (Figure) (Electronic Supplementary Material, Videos 1 and 2). The patient was started on vancomycin and ceftriaxone. Subsequent cardiac magnetic resonance imaging confirmed an aortic root abscess and a 5-mm area of linear mobile density on the ventricular side of the aortic valve prosthesis. Renal biopsy indicated interstitial nephritis with one granuloma, for which she was again started on high-dose steroids. She continued to deteriorate, however, with worsening renal function and developed pancytopenia requiring daily red blood cell and platelet transfusions.
Three weeks after hospitalization, her blood cultures were reported to be positive for mycobacterium, and she was started on a four-drug regimen of rifampin, rifabutin, ethambuton, and clarithromycin with dramatic improvement. Speciation of the organism revealed Mycobacterium chimera (M. chimera). At the time of this report, she was actively being followed by our cardiothoracic surgery team for potential aortic valve explantation, aortic root debridement, and redo tissue aortic valve replacement.
This case is being published with the patient's consent.
Discussion
Infections after cardiac surgery are associated with both increased hospital readmission and mortality. 8, 9 In a review of more than 300,000 patients in the Society of Thoracic Surgeons National Cardiac Database, patients with major infections after cardiothoracic surgery were noted to have higher mortality (17.3% vs 3.0%; P \ 0.001) and an increased hospital stay of [ 14 days (47% vs 5.9%; P \ 0.001) compared with patients without major infection. 9 Prosthetic valve endocarditis is one such major infection that can lead to valve malfunction, subsequent surgical intervention, and other systemic disease. It occurs in 1-6% of patients with prosthetic valves. 10 Non-tuberculous mycobacteria is a known cause of sternal wound infections, prosthetic valve endocarditis, and other postcardiac surgery related infections. [11] [12] [13] [14] [15] [16] The first cases of NTM endocarditis in 1976 were nosocomial and were associated with porcine valves infected with NTM resistant to the formaldehyde used for sterilization. 16 In recent years, clusters of M. chimera cases have been reported in Canada, Europe, and the United States. 17 In 2015, six cases were reported from Zurich in thoracic surgery patients who were found to have infection of the intrathoracic prosthesis. The patients presented with fever, weight loss, pancytopenia, renal failure, fatigue, and granulomatous disease (granulomatous hepatitis, endocarditis and myocarditis, nephritis, osteomyelitis). 6 At the time, the source of infection was believed to be from aerosolized water droplets from the HCUs because water samples in the HCUs and air samples obtained in the operating room were both positive for the same strain of NTM. 7 Subsequently, Germany and The Netherlands reported NTM cases connected to HCUs. 7, 18 In July 2015, a cluster of invasive NTM was reported in Pennsylvania. 19 All reported cases involved a latency period of up to five years after surgery, although the subject of specific precipitant factors for recrudescence of the dormant disease was not addressed. The recognition of HCU infections in Europe and the United States prompted field investigations by the Centers for Disease Control, and speculation arose that the HCUs' original manufacturing process may have been the source of contamination. It was found that all of these HCUs were from the same manufacturer -LivaNova (London, UK), previously Sorin Group (Munich, Germany) -which supplied 60% of all HCUs in the United States. 20 The company initiated investigations and changed its disinfection and drying process in mid-August 2014. In December 2015, information was released regarding six water samples contaminated with M. chimera, two from known contaminated HCUs, three from new units, and one from a sample taken in the pump assembly area at the manufacturing site. 21, 22 In light of these new data, the United States Food and Drug Administration and the Centers for Disease Control issued guidelines to cardiac surgery centers to 1) direct the HCU exhaust vent away from the surgical field to mitigate the risk of aerosolizing tank water into the sterile field; 2) use only sterile water that has been passed through a \ 0.22 lm filter; 3) strictly adhere to the disinfection instructions of the manufacturer; 4) remain vigilant for infections in patients who had undergone surgery in an operating theatre that used LivaNova HCUs manufactured prior to September 2014; and 5) continue to monitor upcoming reports. 20, 23 LivaNova continues to encourage proper cleaning and maintenance of machines. It believes that, if these steps are properly followed, the machines ''pose minimal risk to NTM transmission''. 24 Mycobacteria infections linked to contaminated HCUs pose a diagnostic challenge because the incidence is low and symptoms often do not develop until years after exposure during cardiac surgery. The present case represents a latent NTM likely originating from exposure to a LivaNova HCU manufactured prior to September 2014. Given the chronology of symptom onset after steroid use, we postulate that the repeated episodes of steroidrelated immunosuppression 25 may have precipitated and exacerbated the patient's latent infection. Case reports previously have not focused on precipitating factors that activate latent NTM. It is thus of utmost importance that not only must HCUs be vigilantly cleaned according to the manufacturer's recommendations but also that health care leaders must be continually mindful of new developments regarding NTM infection, its presentations, and its precipitating factors.
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